

## PROPOSITIONS - STELLINGEN

Belonging to this thesis - Behorend bij het proefschrift

### PlcKIng the right treatment for the right patient

1. *PIK3CA* mutations are just the beginning in discovering potential prognostic and predictive biomarkers for anti-hormonal sensitivity in breast cancer (*this thesis*).
2. *LRG1* is a luminal subtype independent biomarker related to *PIK3CA* genotype and AI therapy outcome in advanced breast cancer (*this thesis*).
3. Nuclear phospho-MAPK1/3 expression is a prognostic biomarker in breast cancer (*this thesis*).
4. Decreased expression of *ABAT* is associated with poor anti-hormonal therapy outcome in metastatic breast cancer, as well as adjuvant tamoxifen outcome (*this thesis*).
5. Liquid biopsy is the future for testing potential biomarkers for treatment responsiveness, but it is limited as a ctDNA cancer-screening tool. (Newman, A. M., et al. *Nat Med.* 2014 May;20(5):548-54).
6. In few years drug screening on CTCs will be the standard test to PlcK the right treatment for the right patient. (Yu M., et al. *Science.* 2014 Jul 11;345(6193):216-20).
7. Negative results are also warranted, since "Absence of evidence is not evidence of absence" (Altman D.G., et al. *BMJ.* 1995 Aug 19;311(7003):485).
8. More-sensitive techniques for ctDNA detection do not overcome the problem that ctDNA may hint at the presence of an unknown undetected cancer (Diaz and Diehn. *Nature.* 2014 Jul 31;511(7511):524-6).
9. Thousand patients require thousand cures. *Ovid (43 BC – 17)*.
10. It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has. *William Osler (1849-1919)*.
11. Love is merely a sleight of hand, doled out by genetic edict in order to keep DNA flowing. *Nick Sagan, Idlewild (2003)*.

Diana Esperanza Ramírez Ardila  
17 jan 2018